Kalata B1 vs Pexiganan — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Kalata B1 is the prototype cyclotide - a cyclic peptide with a head-to-tail backbone cyclization and three disulfide bonds forming a cystine knot topology. Isolated from the plant Oldenlandia affinis, which is traditionally used in Africa to accelerate childbirth (uterotonic use)...
Calculate Kalata B1 dose →Pexiganan (MSI-78) is a synthetic analog of magainin-2, optimized for enhanced broad-spectrum antimicrobial activity and reduced hemolytic toxicity. It was developed by Magainin Pharmaceuticals (later Genaera) as a topical treatment for mildly infected diabetic foot ulcers....
Calculate Pexiganan dose →| Parameter | Kalata B1 | Pexiganan |
|---|---|---|
| Category | Antimicrobial Peptide | Antimicrobial Peptide |
| Research | Preclinical | Phase 3 (Failed 1999) |
| Half-Life | Hours (resistant to all proteases) | Hours (topical) |
| Typical Dose | N/A | 0.8% cream topically |
| Frequency | N/A | Twice daily |
| Route | Research only (oral stability under study) | Topical cream |
| FDA Status | Not approved | Not approved (failed Phase 3) |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.